Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 828

1.

Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.

Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, Cahn JY, Passweg JR, Rowlings PA, Schouten HC, Kolb HJ, Klein JP.

N Engl J Med. 1999 Jul 1;341(1):14-21.

2.

Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.

Barrett AJ, Ringdén O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz KR, Tiberghien P.

Blood. 2000 Jun 1;95(11):3323-7.

3.

Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.

Enright H, Davies SM, DeFor T, Shu X, Weisdorf D, Miller W, Ramsay NK, Arthur D, Verfaillie C, Miller J, Kersey J, McGlave P.

Blood. 1996 Jul 15;88(2):714-20.

4.

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M.

Bone Marrow Transplant. 2004 Oct;34(8):721-7.

PMID:
15322568
5.

Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry.

Bortin MM, Horowitz MM, Gale RP.

Nat Immun Cell Growth Regul. 1988;7(5-6):334-50.

PMID:
3065641
6.

Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group.

Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF, Nekolla E, Ljungman P, Jacobsen N, van Weel M, Wick R, Weiss M, Prentice HG.

Ann Intern Med. 1999 Nov 16;131(10):738-44.

PMID:
10577296
7.

Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group.

Phillips GL, Barnett MJ, Brain MC, Chan KW, Huebsch LB, Klingemann HG, Meharchand J, Reece DE, Rybka WB, Shepherd JD, et al.

Bone Marrow Transplant. 1991 Dec;8(6):477-87.

PMID:
1790428
8.

Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W, de Witte T, Kolb HJ, Niederwiser D, Jacobsen N, Gahrton G, Bandini G, Carreras E, Bacigalupo A, Michallet M, Ruutu T, Reiffers J, Goldman JM, Apperley J, Gratwohl A.

Bone Marrow Transplant. 1997 Oct;20(7):553-60.

9.

Allogeneic bone marrow transplantation for leukemia in Europe: regional differences. Report from the Leukemia Working party of the European Group for Bone Marrow Transplantation.

Gratwohl A, Hermans J, Barrett AJ, Ernst P, Frassoni F, Gahrton G, Granena A, Kolb HJ, Prentice HG, Vernant JP, et al.

Bone Marrow Transplant. 1990 Mar;5(3):159-65.

PMID:
2331536
10.

Allogeneic bone marrow transplant in Belfast--an outcome overview of the first 25 years.

Cargo CA, Yates E, Marley C, Piggott S, McMullin MF, Jones FG.

Ulster Med J. 2008 Sep;77(3):185-90. No abstract available.

11.

Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.

Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS.

Bone Marrow Transplant. 2007 Jun;39(12):751-7.

PMID:
17450185
12.

Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors.

Schiller G, Feig SA, Territo M, Wolin M, Lill M, Belin T, Hunt L, Nimer S, Champlin R, Gajewski J.

Br J Haematol. 1994 Sep;88(1):72-8.

PMID:
7803259
13.

Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.

Arcese W, Goldman JM, D'Arcangelo E, Schattenberg A, Nardi A, Apperley JF, Frassoni F, Aversa F, Prentice HG, Ljungman P, et al.

Blood. 1993 Nov 15;82(10):3211-9.

15.

[Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].

Tomás JF, Peñarrubia MJ, García JA, Figuera A, Gómez-García de Soria V, Steegmann JL, Arranz R, Cámara R, Gabriel R, Vázquez L, et al.

Med Clin (Barc). 1995 Nov 11;105(16):605-11. Spanish.

PMID:
8523939
16.

Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry.

Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, Horowitz MM.

Blood. 2000 Jan 15;95(2):410-5.

17.

Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ringdén O, Labopin M, Frassoni F, Sanz G, Demeocq F, Prentice H, Cahn JY, Barbui T, Meloni G, Schaefer U, Reiffers J, Gorin N.

Bone Marrow Transplant. 1999 Aug;24(4):389-96.

18.

Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).

Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringdén O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl A.

Blood. 2000 Jun 15;95(12):3702-9.

19.

Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation.

Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF, Weiss M, Cohen A, Nekolla E, Kolb HJ.

Ann Intern Med. 1997 Feb 1;126(3):184-92.

PMID:
9027268
20.

Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.

Davies SM, DeFor TE, McGlave PB, Miller JS, Verfaillie CM, Wagner JE, Weisdorf DJ.

Am J Med. 2001 Apr 1;110(5):339-46.

PMID:
11286947

Supplemental Content

Support Center